Society of Diabetic Nephropathy Prevention Journal of Nephropharmacology 2345-4202 15 2 2026 07 01 Remission revolution; redefining CKD management from slowdown to reversal e12855 e12855 10.34172/npj.2026.12855 EN Sepideh Hajian https://orcid.org/0000-0002-3368-0036 Azadeh Zahedi Far https://orcid.org/0009-0009-4054-5199 Journal Article 10.34172/npj.2026.12855 2026 02 23 2026 05 06 Chronic kidney disease (CKD) has historically been managed with a traditional mindset focused solely on delaying dialysis initiation rather than restoring renal function. This entrenched paradigm is shifting due to emerging evidence suggesting that significant disease regression and clinical remission are achievable goals. Here, we examine the therapeutic landscape transforming CKD management from mere slowdown to potential reversal. We discuss on sodium glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon like peptide 1 receptor agonists alongside lifestyle modifications including dietary protein restriction and blood pressure optimization. Data indicates that early intervention targeting hemodynamic stress, systemic inflammation, and renal fibrosis can restore glomerular filtration rates (GFRs) and reduce albuminuria below nephrotic thresholds. Furthermore, clinical guidelines should evolve to prioritize remission criteria, emphasizing on aggressive early treatment windows before irreversible scarring occurs. This remission revolution necessitates a fundamental change in physician expectations and patient education, moving away from inevitable decline toward active restoration. Finally, redefining success in CKD care requires integrating these novel agents into standard practice to halt progression and actively reverse damage, offering renewed hope and improved long term outcomes for the future global CKD population while significantly reducing the economic burden associated with end stage renal disease therapy.